Abstract 113P
Background
Tumor tissue preservation methods affect proteome profiles differently. To date, no studies have reported a deep proteome comparison of four tissue preservation methods and their corresponding proteome profiles. This study sought to assess the effect of different preservation methods on quantitative proteomics of human breast adjacent normal (NC) and tumor tissues (TC) preserved in Allprotect, snap-frozen by LN2, RNAlater, and formalin solution embedded in paraffin (FFPE).
Methods
Around 7 patients’ TC and NC were preserved in four different storage conditions, which include Allprotect, LN2, RNAlater, and FFPE. A comprehensive deep proteomics analysis using mass spectrometry has been performed to evaluate the effect of storage conditions on the preservation of proteins. Protein yield and coverage were compared in four storage conditions to determine the optimum storage conditions for tissue samples to perform proteomics analysis. Unique proteins obtained from each condition were further analyzed to examine the effect of storage conditions on subcellular location. Differential analysis was performed on all individual conditions to compare the unique statistically differentially expressed proteins.
Results
TC tissues showed the highest protein yield compared to NC because the fat portion was higher in NC. The FFPE condition, followed by RNAlater, was determined to have the maximum protein coverage. Unique proteins could be detected from FFPE samples, providing a hint of the modifications induced during the paraffinization. However, the differential analysis showed more unique proteins in the Allprotect storage conditions, followed by RNAlater. The proteins CNDP2 and PLIN4 showed dysregulation in the TC sample despite the different storage conditions and may be used as therapeutic markers for breast cancer. Biological pathway analysis showed spliceosome and PPAR signaling pathways were enriched in TC compared to NC tissue.
Conclusions
This study evaluated the effects of different tissue preservation methods on proteomics analysis.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
IIT Bombay.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
30P - Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma
Presenter: Olha Burtyn
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Identification of proteins associated with mRNA processing and maturation by quantitative proteomic analysis in Indian cervical cancer patients
Presenter: Amrita Mukherjee
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients
Presenter: Katerina Dvorakova
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Unraveling the mechanisms of cisplatin resistance in bladder organoid by single cell RNA sequencing
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
Presenter: Jelena Dinić
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
Presenter: Lee Ellis
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Comparison of pelitinib, tepotinib or docetaxel efficacy according to the copy number or gene alteration status of EGFR, MET, HRAS, KRAS and NRAS genes
Presenter: Dae Young Zang
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer
Presenter: Malcolm Ryan
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - The use of antibiotics or proton pump inhibitors and the response to intravesical Bacillus Calmette Guérin therapy in non-muscle-invasive bladder cancer
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - YAP1 promotes sorafenib resistance by activation of TGFβ signaling pathway
Presenter: Chit Lai Chee
Session: Cocktail & Poster Display session
Resources:
Abstract